Review

Antibacterial Peptides in Dermatology—Strategies for Evaluation of Allergic Potential

Milena Deptuła 1,†, Anna Wardowska 2,†, Maria Dzierżyńska 3,*, Sylwia Rodziewicz-Motowidlo 3 and Michał Pikula 2,*

1 Department of Embryology, Medical University of Gdańsk, 80-211 Gdańsk, Poland; milenadepultua@gumed.edu.pl
2 Department of Clinical Immunology and Transplantology, Medical University of Gdańsk, 80-211 Gdańsk, Poland; anna.wardowska@gumed.edu.pl
3 Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, 80-308 Gdańsk, Poland; maria.smuzynska@ug.edu.pl (M.D.); s.rodziewicz-motowidlo@ug.edu.pl (S.R.-M.)
* Correspondence: pikula@gumed.edu.pl; Tel.: +48-58-349-15-92; Fax: +48-58-349-15-91
† These authors contributed equally to this work.

Received: 20 January 2018; Accepted: 13 February 2018; Published: 14 February 2018

Abstract: During recent decades, the market for peptide-based drugs, including antimicrobial peptides, has vastly extended and evolved. These drugs can be useful in treatment of various types of disorders, e.g., cancer, autoimmune diseases, infections, and non-healing wounds. Although peptides are less immunogenic than other biologic therapeutics, they can still induce immune responses and cause allergies. It is important to evaluate the immunogenic and allergic potential of peptides before they are forwarded to the expensive stages of clinical trials. The process of the evaluation of immunogenicity and cytotoxicity is complicated, as in vitro models and bioinformatics tools cannot fully simulate situations in the clinic. Nevertheless, several potentially promising tests for the preclinical evaluation of peptide drugs have been implemented (e.g., cytotoxicity assays, the basophil activation test, and lymphocyte activation assays). In this review, we focus on strategies for evaluation of the allergic potential of peptide-based therapeutics.

Keywords: peptides; antimicrobial peptides; immunogenicity; allergy; toxicity

1. Introduction

Peptides are small molecules that build from 50 or fewer amino acids [1]. They can be designed based on natural bioactive peptides/proteins present in plants, animals, and humans; naturally occurring fragments of enzymes; peptide hormones or host defense peptides; and even structures found in fungi, bacteria, or viruses [2–5]. Their advantages, e.g., good efficacy, safety, tolerability, high selectivity, potency, predictable metabolism, and standard synthetic protocols, make them promising candidates for use as drugs, and are thus of increasing interest in that field. Peptides generally have low oral bioavailability, they are susceptible to metabolizing factors, and they can be cleared from the circulation within minutes. Nowadays, alternatives to the oral route of administration, such as subcutaneous, intravenous, or intramuscular, have become accepted in clinical routines. Moreover, peptides that show high biological activity are taken into consideration as potential biopharmaceuticals [6–8]. The increasing interest in proteins and peptides as drug candidates may also be attributed to the development of chemical and biotechnological methods for large-scale manufacturing of proteins and polypeptides. In addition, currently available analytical methods make the roles of peptides in pathological conditions more comprehensible. Peptides are also easier to modify than standard organic compounds, and thus their propensity to be rapidly metabolized may be reduced. They may, for example, undergo N-terminal esterification (phosphoester) [9] or pegylation modifications [10], which make
them resistant to exopeptidases. These modifications may also have an impact on the reduction of immunogenicity [11,12], and pegylation, which enlarges proteins, can reduce renal clearance [13].

Peptides are not only easy to modify but also to conjoin. Joining two active sequences may lead to a bifunctional compound, which is able to fight primary disease and help restore homeostasis (for example a conjoined antimicrobial peptide with a pro-proliferative sequence [14]). Moreover, the functional comprehensiveness and structural variety of peptides makes them excellent candidates for use in conjugations of biomolecules.

In the world of bioconjugate chemistry, antimicrobial peptides (AMP) hold a prominent position. As the increase in the emergence of multi-drug resistant pathogenic microorganisms has become one of the biggest problems in modern medicine, peptides seem to be a promising alternative to classic antimicrobial agents [15]. AMPs are a part of host defense mechanisms and mostly possess dual activity. Their functions are linked to their origin, i.e., the direct killing of microbes [16], the recruitment of leukocytes and the induction of cytokine/chemokine release [17], the promotion of angiogenesis [18], wound healing [19], mast cell degranulation [20], and the neutralization of endotoxins [21]. AMPs exert strong activity against various microbes (bacteria, fungi, and viruses), including multidrug-resistant strains. The risk of acquiring pathogen resistance to such bioactive compounds is low. However, peptides may be cytotoxic to human cells [22–24].

The story of therapeutic peptides begins with insulin [25] (manufactured by recombinant DNA technology in E. coli [26]) and oxytocin (produced by chemical synthesis elaborated by du Vigneaud in 1953 [27]), which are the most recognizable manufactured peptide hormones. Peptides show potency in treatment of cancer, asthma, neuropathic pain, stroke, diabetes, HIV, heart disease, and wound healing [14,28,29]. Some peptides also have immunoregulatory and anti-inflammatory properties, thanks to which they can be used in the treatment of autoimmune diseases [30,31]. Currently, approximately 140 peptides are undergoing various clinical trials, and more than 500 peptide compounds are being subjected to preclinical trials in order to become potential therapeutics. It is worth mentioning that the market for peptide and protein drugs makes up about 10% of the entire pharmaceutical market and, by 2015, the FDA had approved more than 60 peptide medicines [32,33]. In this mini-review, we would like to discuss peptide immunogenicity and the risk of inducing allergies, as well as methods potentially useful in the prediction of these features.

2. Adverse Reactions to Biological Drugs

Peptides, which are not classified as traditional biological drugs, can exert immunogenic properties similar to proteins [34]. Adverse reactions to biological products differ from those caused by standard chemotherapeutics. Unwanted effects are more common for chemically synthesized proteins and peptides than for compounds naturally present in the human body. A peptide’s influence on the immune system can be multi-directional and depends on host individual immune reactivity, dose, duration of treatment and dosing frequency, treatment scheme (other pharmaceuticals) and, last but not least, the type of the patient’s disease [35–37]. Product source can also have an impact on its immunogenicity: for example, recombinant human insulin is less immunogenic than porcine insulin [38]. The route of administration is important as well. Generally, the highest risk of inducing an immune response is after the subcutaneous route of administration, followed by intramuscular, intranasal, and intravenous routes [39,40]. Immunogenicity of peptides or proteins can potentially affect their efficiency and lead to adverse reactions such as allergy or hypersensitivity [41]. Biologics may induce secretion of pro-inflammatory cytokines, as well as stimulate T cells, basophils/mast cells (allergic reactions), or neutrophils [36,42,43]. These compounds can also stimulate production of neutralizing or non-neutralizing anti-drug antibodies (ADAs). Neutralizing antibodies, present only in a small percentage of treated patients, cause negative consequences due to neutralization of a therapeutic product, thereby reducing its efficiency [39]. For instance, 40% of patients treated for multiple sclerosis (MS) with interferon beta (INF-β) develop ADAs (mostly neutralizing), which is associated with loss of efficiency of the INF-β treatment [44]. On the other hand, a majority
of patients develop non-neutralizing antibodies, which do not significantly affect therapeutic effects of the drug [39]. Formation of ADAs can cause infusion reactions and anaphylaxis [45,46], immune complex-mediated diseases [47], and even such serious conditions as thrombocytopenia or pure red cell aplasia [48,49]. It is more likely that patients who develop ADAs will suffer from acute hypersensitivity reactions [50].

Although ADAs generally represent the IgG isotype, some complications may be caused by IgE-mediated immune responses. These responses may include local skin reactions or systemic reactions like anaphylaxis, which can potentially threaten a patient’s life. However, severe reactions are rare and more often associated with administration of xenopeptides or drug re-administration [50,51]. Moreover, some acute reactions can be antibody-independent and caused by cytokine release [50].

### 3. Tests Useful in Prediction of Peptide Immunogenicity and Allergic Potential

In general, peptides are less immunogenic than recombinant proteins and antibodies, but they can induce immune responses and allergies. The effects of peptides on the immune system depend on the compounds’ physicochemical properties and amino-acid sequence [52]. Although their features, like absorption and transport through biological membranes and barriers, are predictable, based on their physicochemical properties (such as water solubility, lipophilicity, proneness to forming H-bonds, chemical stability, and inclination to succumbing to proteolytic degradation [53]), their immunogenicity and risk of inducing allergy is difficult to predict. Based on our experience in evaluation of AMPs in wound healing, we can assume that there are a few in vitro test and bioinformatics tools that can be useful in evaluation of allergic potential and immunogenicity (Figure 1). Even though these tests cannot fully simulate immune responses in the clinic, they can be helpful in preclinical testing of different protein or peptide drugs [54,55]. In addition, it is important to use human cells, as the immune reactions observed in animal studies may differ significantly from human reactivity [42].

![Figure 1. Preclinical evaluation of AMPs.](image-url)

### 3.1. Peptide Cytotoxicity

In addition to the fact that peptides can be cytotoxic to human cells, there is a need to analyze their influence on living cells. Colorimetric methods, such as an MTT assay (and its modifications) or an LDH assay can be a first step in screening of peptide drug candidates. The MTT assay is based on living cells’ ability to reduce tetrazolium salts to formazan. The LDH test measures the activity of lactate dehydrogenase (LDH), which is released by dead or membrane-damaged cells, in culture supernatants. This initial screening allows introduction of appropriate modifications to the tested peptides, leading to the strengthening of their biological activity or reduction of their side effects and toxicity [24]. Human skin cells can be used to evaluate the cytotoxicity of antimicrobial peptides. Barańska-Rybak et al. [56] showed that antimicrobial peptides can have different effects on human HaCaT keratinocytes, depending on their structure. In that study, most of the tested
peptides were not toxic to human cells at their minimal inhibitory concentrations. Only lipopeptide exerted strong antiproliferative activity against HaCaT cells, which may be connected to its chemical properties including hydrophobicity. It is also crucial to choose an appropriate in vitro model for toxicity assessment. Transformed human skin cell lines, e.g., the HaCaT keratinocyte cell line, which reflect the properties of primary cells, provide reliable and reproducible results. They also prevent donor-to-donor variability from existing in primary cell lines isolated from human skin samples [14]. However, the significant variability between the reactivity of primary and transformed human cells lines cannot be excluded.

3.2. Basophil Activation Assay (BAT)

The basophil activation test (Figure 2) allows the detection of hypersensitivity reactions in vitro by flow cytometry. It is a routine test used for the evaluation of the allergic potential of various drugs, including antibiotics [57]. It relies on flow cytometric identification and quantification of changes in activation of markers on the surface of basophils, detected with specific monoclonal antibodies coupled to fluorochromes [56]. The BAT is more expensive and technically more advanced than other available in vitro and in vivo tests, but it allows safe prediction of the allergenicity of different compounds [59]. It can be used to determine the allergic potential of new prospective drugs, like peptides and other biologics, and may be an alternative to provocation tests [58]. Flow cytometric analysis of activated basophils may be performed on whole blood or on basophils isolated by buffy coat centrifugation or dextran sedimentation. However, a whole blood assay is preferred, as it can be more efficient [60]. In the BAT protocol, whole blood basophils are challenged with the tested compound or one of the basophil activators anti-FcεRI or fMLP, which activates basophils in an immunologic or nonimmunologic way. The expression of three markers is then checked: CCR3 (basophil population marker) and CD63 and CD203c (markers of basophil activation) [61]. In our laboratory, we have used the BAT test to evaluate the allergic potential of antimicrobial compounds (A20, camel, citropin). The results showed that antimicrobial peptides and peptidomimetics can have different allergic potentials. A20, also called Cystapep 1 (peptidomimetic), did not activate basophils obtained from healthy donors, but camel and citropin (peptides) had an allergic potential in hypersensitive patients [54,61]. This shows that people suffering from allergies should be taken into consideration in preclinical testing of new potential peptide drugs.

![Figure 2](image_url)

**Figure 2.** Representative dot plots (based on our own data) showing gating strategy of basophils based on low SSC-A values and high CCR-3 expression (A); Basophils were displayed in a graph with CCR3-PE on the x-axis and CD63 FITC on the y-axis; negative control (B); cells activated with stimulating antibodies (C); cells stimulated by bacterial tripeptide-fMLP (D).

3.3. Cytokine Assays and Lymphocyte Activation Analysis

Measurement of the release of Th2 response cytokines (IL-4, IL-5, IL-13) by human Peripheral Blood Mononuclear Cells (PBMCs), by the ELISPOT method, can also be used in preclinical testing. These cytokines are accountable for human allergic inflammation [62]. This evaluation method can be used in two ways. First, incubation of PBMCs with the tested peptide will show whether the compound
can activate PBMCs and stimulate the release of Th2 cytokines, therefore indicating an allergic or immunogenic potential. Second, challenging of activated PBMCs (e.g., by Concanavalin A, a T-cell mitogen, which stimulates release of different cytokines) with the tested peptide can show whether it decreases secretion of cytokines and exerts immunomodulatory properties. Release of TNF-α, an early marker of immune system activation, by PBMCs can also be assessed [61]. The secretion of proinflammatory cytokines (i.e., TNF-α, IL-1 etc.) may indicate an inflammatory potential of the analyzed compound or even imply a higher risk of allergy induction. Another way to evaluate the immunogenic or allergic potential of the examined compounds is an assessment of activation marker expression on cells by flow cytometry analysis. This very useful and comprehensive method enables checking of whether selected PBMCs subpopulations activate in presence of the analyzed peptides. The majority of tests focus on various T cell subpopulations, as they play a pivotal role in immune responses; for example, T helper cells (Th), upon immunogenic peptide stimulation, increase expression of three major activation markers, namely CD25, CD69, and CD71 [63,64]. The cells participate in lymphocyte B activation and their antibodies participate in IgE production, thus contributing to an allergic reaction [65].

3.4. Bioinformatics Tools

As allergenic proteins from different sources can have similar sequences and structures, databases and bioinformatics search tools can be helpful in prediction of the allergic potential of peptides. The Structural Database of Allergenic Proteins (SDAP) is an online database that contains information on over 800 allergens and can be used to find structural and functional similarities of designed peptides to known allergens [66]. The property distance index (PD), calculated based on comparison of a peptide sequence and sequences in SDAP, allows prediction of IgE cross-reactivity and allergic potential. According to literature data, a PD value cutoff between 7.5 and 9.0 is suitable for determination of peptides with similar properties. Peptides with no similarities to SDAP have PD values much higher than 10 [54,67]. Our previous study showed that synthetically produced antimicrobial peptides (citropin and camel) are structurally similar to common environmental allergens. Combining the results of the database search with a BAT test proved to be useful in the assessment of the risk of allergic reaction induction by potential peptide drugs [50].

Another strategy for allergic potential evaluation may be an assessment of peptide binding to MHC class II receptors. HLA class II molecules mediate the response of CD4 T-cells to exogenously administrated proteins. [68]. Dhanda et al. [69] evaluated a new computational tool for prediction of “de-immunized” peptides. Their approach was based on the fact that HLA binding is crucial for T-cell immunogenicity and, if HLA binding is decreased or abolished, there is an expected decrease in protein/peptide immunogenicity. Their method predicts binding regions on a protein sequence and identifies residue substitutions that can reduce HLA binding. They used this program to select factor VII analogues with reduced immunogenicity. This algorithm correctly predicted two immunogenic peptides for which in vitro tests on human PBMCs showed positive responses in 46% of cultures. In the next step, they evaluated the immunogenicity of seven substitutions that were predicted to simultaneously reduce HLA binding for both peptides. In in vitro tests they showed immunogenicity in 21.4% of PBMCs cultures. Their results show that this online tool can be useful in searching for peptides with reduced immunogenicity.

4. Conclusions

The immunogenicity of peptide-based and protein drugs, which can affect their efficiency and cause unwanted side effects, is an important consideration in the biological evaluation of these potential therapeutics. It is crucial to check their immunogenic or allergic potential before these drug candidates are subjected to expensive clinical trials. In vitro immunological tests, as well as bioinformatics tools and databases, despite being a simplification of naturally occurring systemic reactions, comprise a valuable tool in the assessment of potential peptide therapeutics. It is therefore
of great value to elaborate and implement new, more accurate, preclinical tests based on, e.g., 3D tissue models, organ-on-a-chip, or lymphoid tissue-like organoids.

Acknowledgments: This work was supported by funds of the National Centre for Research and Development, Poland, grant No. STRATEGMED1/235077/9/NCBR/2014 and of the Polish National Science Centre based on the decision No. 2012/05/D/NZ5/01224.

Author Contributions: M.D. and A.W. designed, wrote the manuscript and prepared Figures 1 and 2, M.Dz. designed, wrote a chemical part of the manuscript, S.R.-M. supported financially and corrected the manuscript, M.P. conceived, designed and corrected the manuscript and supervised the project.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Komin, A.; Russell, L.M.; Hristova, K.A.; Searson, P.C. Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges. Adv. Drug Deliv. Rev. 2017, 110–111, 52–64. [CrossRef] [PubMed]
2. Prabhu, S.; Dennison, S.R.; Lea, B.; Snape, T.J.; Nicholl, I.D.; Radecka, I.; Harris, F. Anionic Antimicrobial and Anticancer Peptides from Plants. Crit. Rev. Plant Sci. 2013, 32, 303–320. [CrossRef]
3. Brener, S.J.; Zeymer, U.; Adgey, A.A.J.; Vrobel, T.R.; Ellis, S.G.; Neuhaus, K.L.; Juram, N.; Ivanc, T.B.; Ohman, E.M.; Strongy, J.; et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The Integrin and Low-Dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) trial. J. Am. Coll. Cardiol. 2002, 39, 377–386. [CrossRef]
4. Garcia-Calvo, M.; Peterson, E.P.; Rasper, D.M.; Vaillancourt, J.P.; Zamboni, R.; Nicholson, D.W.; Thornberry, N.A. Purification and catalytic properties of human caspase family members. Cell Death Differ. 1999, 6, 362–369. [CrossRef] [PubMed]
5. Rizzuti, M.; Nizzardo, M.; Zanetta, C.; Ramirez, A.; Corti, S. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov. Today 2013, 20, 76–85. [CrossRef] [PubMed]
6. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today 2010, 15, 40–56. [CrossRef] [PubMed]
7. Goodwin, D.; Simerska, P.; Toth, I. Peptides as Therapeutics with Enhanced Bioactivity. Curr. Med. Chem. 2012, 19, 4451–4461. [CrossRef] [PubMed]
8. Craik, D.J.; Fairlie, D.P.; Liras, S.; Price, D. The Future of Peptide-based Drugs. Chem. Biol. Drug Des. 2013, 81, 136–147. [CrossRef] [PubMed]
9. Benore-Parsons, M.; Seidah, N.G.; Wennoogle, L.P. Substrate phosphorylation can inhibit proteolysis by trypsin-like enzymes. Arch. Biochem. Biophys. 1989, 272, 274–280. [CrossRef]
10. Lee, S.H.; Lee, S.; Yu, S.Y.; Na, D.H.; Su, Y.C.; Byun, Y.; Lee, K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 2005, 16, 377–382. [CrossRef] [PubMed]
11. He, X.-H.; Shaw, P.-C.; Tam, S.-C. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999, 65, 355–368. [CrossRef]
12. Milton Harris, J.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214–221. [CrossRef] [PubMed]
13. Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10, 1451–1458. [CrossRef]
14. Kosikowska, P.; Pikula, M.; Langa, P.; Trzonkowski, P.; Obuchowski, M.; Lesner, A. Synthesis and evaluation of biological activity of antimicrobial pro-proliferative peptide conjugates. PLoS ONE 2015, 10, 1–16. [CrossRef] [PubMed]
15. Laverty, G.; McLaughlin, M.; Shaw, C.; Gorman, S.P.; Gilmore, B.F. Antimicrobial activity of short, synthetic cationic lipopeptides. Chem. Biol. Drug Des. 2010, 75, 563–569. [CrossRef] [PubMed]
16. Ganz, T.; Selsted, M.E.; Szkwarek, D.; Harwig, S.S.; Daber, K.; Bainton, D.F.; Lehrer, R.I. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Investig. 1985, 76, 1427–1435. [CrossRef] [PubMed]
17. Tani, K.; Murphy, W.J.; Chertov, O.; Salcedo, R.; Koh, C.Y.; Utsumoiya, I.; Funakoshi, S.; Asai, O.; Herrmann, S.H.; Wang, J.M.; et al. Defensins act as potent adjuvant thta promote cellular and humoral immune response in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 2000, 12, 691–700. [CrossRef] [PubMed]
18. Koczulla, R.; Von Degenfeld, G.; Kupatt, C.; Krötz, F.; Zahler, S.; Gloe, T.; Issbrücker, K.; Unterberger, P.; Zaiou, M.; Lebherz, C.; et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J. Clin. Investig.* 2003, 111, 1665–1672. [CrossRef] [PubMed]

19. Steinstraesser, L.; Koehler, T. Host Defense Peptides in Wound Healing. *Mol. Med.* 2008, 14, 528–537. [CrossRef] [PubMed]

20. Oppenheim, J.J.; Biragyn, A.; Kwak, L.W.; Yang, D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. *Ann. Rheum. Dis.* 2003, 62, ii17–ii21. [CrossRef] [PubMed]

21. Fukumoto, K.; Nagaoka, I.; Yamataka, A.; Kobayashi, H.; Yanai, T.; Kato, Y.; Miyano, T. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. *Pediatr. Surg. Int.* 2005, 21, 20–24. [CrossRef] [PubMed]

22. Padhi, A.; Sengupta, M.; Sengupta, S.; Roehm, K.H.; Sonawane, A. Antimicrobial peptides and proteins in mycobacterial therapy: Current status and future prospects. *Tuberculosis* 2014, 94, 363–373. [CrossRef] [PubMed]

23. Bahar, A.; Ren, D. Antimicrobial Peptides. *Pharmaceuticals* 2013, 6, 1543–1575. [CrossRef] [PubMed]

24. Dębowski, D.; Łukajtis, R.; Łe˙gowska, A.; Karna, N.; Pikula, M.; Wysocka, M.; Maliszewska, I.; Sierczycy, M.; Lesner, A.; Rolka, K. Inhibitory and antimicrobial activities of OGTT and HV-BBI peptides, fragments and analogs derived from amphibian skin. *Peptides* 2012, 35, 276–284. [CrossRef] [PubMed]

25. Abel, J.J. Crystaline insulin. *Proc. Natl. Acad. Sci. USA* 1926, 12, 132–136. [CrossRef] [PubMed]

26. Swartz, J.R. Advances in Escherichia coli production of therapeutic proteins. *Curr. Opin. Biotechnol.* 2001, 12, 195–201. [CrossRef]

27. Du Vigneaud, V.; Ressler, C.; Swan, J.M.; Roberts, C.W.; Katsoyannis, P.G.; Gordon, S. The Synthesis of an Octapeptide Amide with the Hormonal Activity of Oxytocin. *J. Am. Chem. Soc.* 1953, 75, 4879–4880. [CrossRef]

28. Tang, J.; Liu, H.; Gao, C.; Mu, L.; Yang, S.; Rong, M.; Zhang, Z.; Liu, J.; Ding, Q.; Lai, R. A small peptide with potential ability to promote wound healing. *PLoS ONE* 2014, 9. [CrossRef] [PubMed]

29. Strzelecka, P.; Czaplinska, D.; Sadej, R.; Wardowska, A.; Pikula, M.; Lesner, A. Simplified, serine-rich theta-defensin analogues as antitumour peptides. *Chem. Biol. Drug Des.* 2017, 90, 52–63. [CrossRef] [PubMed]

30. Ma, Y.; Liu, J.; Shi, H.; Yu, L. Isolation and characterization of anti-inflammatory peptides derived from whey protein. *J. Dairy Sci.* 2016, 99, 6902–6912. [CrossRef] [PubMed]

31. Rahnamaeian, M. Antimicrobial peptides: Modes of mechanism, modulation of defense responses. *Plant Signal. Behav.* 2011, 6, 1325–1332. [CrossRef] [PubMed]

32. Usmani, S.S.; Bedi, G.; Samuel, J.S.; Singh, S.; Kalra, S.; Kumar, P.; Ahuja, A.A.; Sharma, M.; Gautam, A.; Raghava, G.P.S. THPdb: Database of FDA-approved peptide and protein therapeutics. *PLoS ONE* 2017, 12. [CrossRef] [PubMed]

33. Fosgerau, K.; Hoffmann, T. Peptide therapeutics: Current status and future directions. *Drug Discov. Today* 2015, 20, 122–128. [CrossRef] [PubMed]

34. Shankar, G.; Arkin, S.; Cocea, L.; Devanarayan, V.; Kirshner, S.; Kromminga, A.; Quarmby, V.; Richards, S.; Schneider, C.K.; Subramanyam, M.; et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations. *AAPS J.* 2014, 16, 658–673. [CrossRef] [PubMed]

35. Corominas, M.; Gastaminza, G.; Lobera, T. Hypersensitivity reactions to biological drugs. *J. Investig. Allergol. Clin. Immunol.* 2014, 24, 212–225. [CrossRef] [PubMed]

36. Moussa, E.M.; Panchal, J.P.; Moorthy, B.S.; Blum, J.S.; Joubert, M.K.; Narhi, L.O.; Topp, E.M. Immunogenicity of Therapeutic Protein Aggregates. *J. Pharm. Sci.* 2016, 105, 417–430. [CrossRef] [PubMed]

37. Wadhwa, M.; Bird, C.; Dilger, P.; Gaines-Das, R.; Thorpe, R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. *J. Immunol. Methods* 2003, 278, 1–17. [CrossRef]

38. Fineberg, S.E.; Galloway, J.A.; Fineberg, N.S.; Rathbun, M.J.; Hufferd, S. Immunogenicity of recombinant DNA human insulin. *Diabetologia* 1983, 25, 465–469. [CrossRef] [PubMed]

39. Kuriakose, A.; Chirmule, N.; Nair, P. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. *J. Immunol. Res.* 2016, 2016, 1–18. [CrossRef] [PubMed]
40. Fathallah, A.M.; Bankert, B.R.; Balu-Iyer, S.V. Immunogenicity of subcutaneously administered therapeutic proteins—A mechanistic perspective. *AAPS J.* 2013, 15, 897–900. [CrossRef] [PubMed]

41. Singh, S.K.; Cousens, L.P.; Alvarez, D.; Mahajan, P.B. Determinants of immunogenic response to protein therapeutics. *Biologicals* 2012, 40, 364–368. [CrossRef] [PubMed]

42. Shankar, G.; Shores, E.; Wagner, C.; Mire-Sluis, A. Scientific and regulatory considerations on the immunogenicity of biologics. *Trends Biotechnol.* 2006, 24, 274–280. [CrossRef] [PubMed]

43. Stone, S.F.; Phillips, E.J.; Wiese, M.D.; Heddle, R.J.; Brown, S.G.A. Immediate-type hypersensitivity drug reactions. *Br. J. Clin. Pharmacol.* 2014, 78, 1–13. [CrossRef] [PubMed]

44. Kalluri, S.R.; Grummel, V.; Hracsko, Z.; Pongratz, V.; Permpintner, V.; Gasperi, C.; Buck, D.; Hemmer, B. Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. *J. Autoimmun.* 2017. [CrossRef] [PubMed]

45. Lichtenstein, L.; Ron, Y.; Kivity, S.; Ben-Horin, S.; Israeli, E.; Fraser, G.M.; Dotan, I.; Chowers, Y.; Confino-Cohen, R.; Weiss, B. Inflimiximab-Related Infusion Reactions: Systematic Review. *J. Crohn’s Colitis* 2015, 9, 806–815. [CrossRef] [PubMed]

46. Vultaggio, A.; Matucci, A.; Nencini, F.; Pratesi, S.; Parronchi, P.; Rossi, O.; Romagnani, S.; Maggi, E. Anti-inflimiximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. *Allergy Eur. J. Allergy Clin. Immunol.* 2010, 65, 657–661. [CrossRef] [PubMed]

47. Korowski, L.A.; Bartelds, G.M.; Kriek, C.L.M.; Turkstra, F.; Nurmohamed, M.T.; Van Schaardenburg, D.; Wijbrands, C.A.; Tak, P.P.; Lems, W.F.; Dijkmans, B.A.C.; et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study. *Arthritis Rheum.* 2011, 63, 877–883. [CrossRef] [PubMed]

48. Aster, R.H.; Curtis, B.R.; McFarland, J.G.; Bougie, D.W. Drug-induced immune thrombocytopenia: Pathogenesis, diagnosis, and management. *J. Thromb. Haemost.* 2009, 7, 911–918. [CrossRef] [PubMed]

49. Macdougall, I.C.; Rossert, J.; Casadevall, N.; Casadevall, M.; Froissart, M.; Eckardt, K.U. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. *N. Engl. J. Med.* 2009, 361, 1848–1855. [CrossRef] [PubMed]

50. Vultaggio, A.; Maggi, E.; Matucci, A. Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management. *Curr. Opin. Allergy Clin. Immunol.* 2011, 11, 262–268. [CrossRef] [PubMed]

51. Schnabel, C.A.; Fineberg, S.E.; Kim, D.D. Immunogenicity of xenopeptide hormone therapies. *Peptides* 2006, 27, 1902–1910. [CrossRef] [PubMed]

52. Eskandari, S.; Guerin, T.; Toth, I.; Stephenson, R.J. Recent advances in self-assembled peptides: Implications for targeted drug delivery and vaccine engineering. *Adv. Drug Deliv. Rev.* 2017, 110–111, 169–187. [CrossRef] [PubMed]

53. Ladner, R.C.; Sato, A.K.; Gorzelany, J.; De Souza, M. Synthetic therapeutic peptides: Science and market. *Drug Discov. Today* 2008, 8, 40–56. [CrossRef] [PubMed]

54. Pikula, M.; Zieliński, M.; Specjalski, K.; Barańska-Rybak, W.; Dawgul, M.; Langa, P.; Jassem, E.; Kamysz, W.; Trzonkowski, P. In Vitro Evaluation of the Allergic Potential of Antibacterial Peptides: Camel and Citropin. *Chem. Biol. Drug Des.* 2016, 87, 562–568. [CrossRef] [PubMed]

55. Jiskoot, W.; Kijanka, G.; Randolph, T.W.; Carpenter, J.F.; Koulov, A.V.; Mahler, H.C.; Joubert, M.K.; Jawa, V.; Narhi, L.O. Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. *J. Pharm. Sci.* 2016, 105, 1567–1575. [CrossRef] [PubMed]

56. Barańska-Rybak, W.; Pikula, M.; Dawgul, M.; Kamysz, W.; Trzonkowski, P.; Roszkiewicz, J. Safety profile of antimicrobial peptides: Camel, citropin, protegrin, temporin and a lipopeptide on hacat keratinocytes. *Acta Pol. Pharm. Drug Res.* 2013, 70, 795–801.

57. Ebo, D.G.; Bridts, C.H.; Hagendorrens, M.M.; Aerts, N.E.; De Clerck, L.S.; Stevens, W.J. Basophil activation test by flow cytometry: Present and future applications in allergology. *Cytom. Part B Clin. Cytom.* 2008, 74B, 201–210. [CrossRef] [PubMed]

58. Leysen, J.; Sabato, V.; Verweij, M.M.; De Knop, K.J.; Bridts, C.H.; De Clerck, L.S.; Ebo, D.G. The basophil activation test in the diagnosis of immediate drug hypersensitivity. *Expert Rev. Clin. Immunol.* 2011, 7, 349–355. [CrossRef] [PubMed]

59. Song, W.-J.; Chang, Y.-S. Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity. *Asia Pac. Allergy* 2013, 3, 266–280. [CrossRef] [PubMed]
60. Sturm, G.J.; Kranzelbinder, B.; Sturm, E.M.; Heinemann, A.; Groselj-Strele, A.; Aberer, W. The basophil activation test in the diagnosis of allergy: Technical issues and critical factors. *Allergy* **2009**, *64*, 1319–1326. [CrossRef] [PubMed]

61. Pikuła, M.; Smużyńska, M.; Krzystyniak, A.; Zielinski, M.; Langa, P.; Deptula, M.; Schumacher, A.; Łata, J.; Cichorek, M.; Grubb, A.; et al. Cystatin C peptidomimetic derivative with antimicrobial properties as a potential compound against wound infections. *Bioorg. Med. Chem.* **2017**, *25*. [CrossRef] [PubMed]

62. Maggi, E. T-cell responses induced by allergen-specific immunotherapy. *Clin. Exp. Immunol.* **2010**, *161*, 10–18. [CrossRef] [PubMed]

63. Kiernan, C.H.; Hoogduijn, M.J.; Franquesa, M.; Wolvius, E.B.; Brama, P.A.J.; Farrell, E. Allogeneic chondrogenically differentiated human mesenchymal stromal cells do not induce immunogenic responses from T lymphocytes in vitro. *Cytotherapy* **2016**, *18*, 957–969. [CrossRef] [PubMed]

64. Caruso, A.; Licenziati, S.; Corulli, M.; Canaris, A.D.; De Francesco, M.A.; Fiorentini, S.; Peroni, L.; Fallacara, F.; Dima, F.; Balsari, A.; et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. *Cytometry* **1997**, *27*, 71–76. [CrossRef]

65. Pichler, W.J.; Yawalkar, N. Allergic reactions to drugs: Involvement of T cells. *Thorax* **2000**, *55*, 61S–65S. [CrossRef]

66. Schein, C.H.; Ivanciuc, O.; Braun, W. Bioinformatics Approaches to Classifying Allergens and Predicting Cross-Reactivity. *Immunol. Allergy Clin. N. Am.* **2007**, *27*, 1–27. [CrossRef] [PubMed]

67. Ivanciuc, O.; Midoro-Horiuti, T.; Schein, C.H.; Xie, L.; Hillman, G.R.; Goldblum, R.M.; Braun, W. The property distance index PD predicts peptides that cross-react with IgE antibodies. *Mol. Immunol.* **2009**, *46*, 873–883. [CrossRef]

68. Paul, S.; Kolla, R.V.; Sidney, J.; Weiskopf, D.; Fleri, W.; Kim, Y.; Peters, B.; Sette, A. Evaluating the Immunogenicity of Protein Drugs by Applying In Vitro MHC Binding Data and the Immune Epitope Database and Analysis Resource. *Clin. Dev. Immunol.* **2013**, *2013*, 1–7. [CrossRef] [PubMed]

69. Dhanda, S.K.; Grifoni, A.; Pham, J.; Vaughan, K.; Sidney, J.; Peters, B.; Sette, A. Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity. *Immunology* **2018**, *153*, 118–132. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).